Maki Takakuni, Takahashi Yoko, Miyamoto Nobukazu, Liang Anna C, Ihara Masafumi, Lo Eng H, Arai Ken
Neuroprotection Research Laboratory, Departments of Radiology and Neurology, MA General Hospital, Harvard Medical School, USA.
Neuroprotection Research Laboratory, Departments of Radiology and Neurology, MA General Hospital, Harvard Medical School, USA; Department of Developmental Neuroscience, United Centers for Advanced Research and Translational Medicine, Tohoku University School of Medicine, Sendai, Japan.
Stem Cell Res. 2015 Jul;15(1):68-74. doi: 10.1016/j.scr.2015.05.001. Epub 2015 May 9.
Oligodendrocytes, which are the main cell type in cerebral white matter, are generated from their precursor cells (oligodendrocyte precursor cells: OPCs). However, the differentiation from OPCs to oligodendrocytes is disturbed under stressed conditions. Therefore, drugs that can improve oligodendrocyte regeneration may be effective for white matter-related diseases. Here we show that a vasoactive peptide adrenomedullin (AM) promotes the in vitro differentiation of OPCs under pathological conditions. Primary OPCs were prepared from neonatal rat brains, and differentiated into myelin-basic-protein expressing oligodendrocytes over time. This in vitro OPC differentiation was inhibited by prolonged chemical hypoxic stress induced by non-lethal CoCl(2) treatment. However, AM promoted the OPC differentiation under the hypoxic stress conditions, and the AM receptor antagonist AM(22-52) canceled the AM-induced OPC differentiation. In addition, AM treatment increased the phosphorylation level of Akt in OPC cultures, and correspondingly, the PI3K/Akt inhibitor LY294002 blocked the AM-induced OPC differentiation. Taken together, AM treatment rescued OPC maturation under pathological conditions via an AM-receptor-PI3K/Akt pathway. Oligodendrocytes play critical roles in white matter by forming myelin sheath. Therefore, AM signaling may be a promising therapeutic target to boost oligodendrocyte regeneration in CNS disorders.
少突胶质细胞是脑白质中的主要细胞类型,由其前体细胞(少突胶质前体细胞:OPCs)产生。然而,在应激条件下,OPCs向少突胶质细胞的分化会受到干扰。因此,能够促进少突胶质细胞再生的药物可能对白质相关疾病有效。在此,我们表明血管活性肽肾上腺髓质素(AM)在病理条件下可促进OPCs的体外分化。从新生大鼠脑制备原代OPCs,随着时间推移,其分化为表达髓鞘碱性蛋白的少突胶质细胞。这种体外OPC分化受到非致死性CoCl₂处理诱导的长时间化学缺氧应激的抑制。然而,AM在缺氧应激条件下促进了OPC分化,且AM受体拮抗剂AM(22 - 52)消除了AM诱导的OPC分化。此外,AM处理增加了OPC培养物中Akt的磷酸化水平,相应地,PI3K/Akt抑制剂LY294002阻断了AM诱导的OPC分化。综上所述,AM处理通过AM受体 - PI3K/Akt途径在病理条件下挽救了OPC成熟。少突胶质细胞通过形成髓鞘在白质中发挥关键作用。因此,AM信号通路可能是促进中枢神经系统疾病中少突胶质细胞再生的一个有前景的治疗靶点。